In its latest regulatory filing Primecap disclosed it exited its AstraZeneca holding, removing a position that accounted for 2.57% of its equity portfolio. This reduction represents one of the largest shifts in the fund’s healthcare investments for the quarter.

The withdrawal by a major active manager may reduce demand for AstraZeneca shares and introduce downward pressure on the stock. Investors may interpret the move as a sign of decreased confidence in the company’s near-term growth prospects.